<p>MDxHealth SA (NASDAQ:MDXH - 获取免费报告) 在 12 月份的空头头寸大幅减少。截至 12 月 15 日，空头头寸总计 15,027 股，比 11 月 30 日的 26,198 股减少了 42.6%。根据 122,196 股的平均日交易量，当前的覆盖天数比率为 0.1 天。目前，公司股票的空头比例为 0.0%。</p>
<h2>MDxHealth 股价下跌 1.7%</h2>
<p>NASDAQ:MDXH 周五下跌 0.06 美元，报 3.41 美元。该公司的股票交易量为 42,254 股，而其平均交易量为 110,342 股。该股票的 50 日移动平均价格为 3.84 美元，200 日移动平均价格为 3.37 美元。MDxHealth 的 12 个月低点为 1.35 美元，12 个月高点为 5.33 美元。该公司的速动比率为 1.02，流动比率为 1.14，债务股本比率为 13.81。该公司的市值为 1.6126 亿美元，市盈率为-5.33，贝塔值为 1.59。</p>
<p>MDxHealth (NASDAQ:MDXH - 获取免费报告) 最近于 11 月 12 日发布了季度财报。该公司报告每股收益（EPS）为-0.16 美元，低于分析师一致预期的-0.12 美元，差距为 0.04 美元。MDxHealth 的净利润率为-30.50%，股本回报率为-1,078.01%。该公司在本季度的收入为 2743 万美元，而分析师预期为 2411 万美元。平均而言，股票分析师预计 MDxHealth 在当前财政年度的每股收益为-1.15 美元。</p>
<h2>MDxHealth 的机构交易</h2>
<p>大型投资者最近调整了对该股票的持有。GSA Capital Partners LLP 在第三季度购买了 MDxHealth 的新股份，价值约 48,000 美元。Lido Advisors LLC 在第三季度获得了 MDxHealth 的新头寸，价值约 48,000 美元。Citadel Advisors LLC 在第三季度将其在 MDxHealth 的持股增加了 30.6%。Citadel Advisors LLC 目前拥有 48,938 股该公司的股票，价值 228,000 美元，此前在上个季度购买了 11,456 股。Jefferies Financial Group Inc.在第三季度获得了 MDxHealth 的新股份，价值约 53,000 美元。最后，Bank of America Corp DE 在第三季度将其在 MDxHealth 的持股增加了 5,164.0%。Bank of America Corp DE 目前拥有 15,055 股该公司的股票，价值 70,000 美元，此前在该期间内购买了 14,769 股。</p>
<h2>华尔街分析师预测增长</h2>
<p>一些股票分析师最近对 MDXH 股票发布了报告。Weiss Ratings 在 10 月 8 日的研究报告中重申了对 MDxHealth 股票的 “卖出（e+）” 评级。Wall Street Zen 在 8 月 30 日的报告中将 MDxHealth 股票的评级上调至 “持有”。Lake Street Capital 在 11 月 13 日的研究报告中将 MDxHealth 的目标价格从 7.00 美元上调至 9.00 美元，并给予该股票 “买入” 评级。BTIG Research 在 12 月 23 日的报告中重申了 “买入” 评级，并对 MDxHealth 股票设定了 7.00 美元的目标价。最后，TD Cowen 在 11 月 13 日的报告中将 MDxHealth 的目标价格从 5.00 美元上调至 7.00 美元，并给予该股票 “买入” 评级。四位分析师对该股票给予了买入评级，一位分析师对该公司的股票给予了卖出评级。根据 MarketBeat.com 的数据，MDxHealth 目前的共识评级为 “适度买入”，共识目标价格为 7.75 美元。</p>
<p><strong>查看我们关于 MDxHealth 的最新报告</strong></p>
<h2>关于 MDxHealth</h2>
<p>(获取免费报告)</p>
<p>MDxHealth 总部位于比利时梅赫伦，在美国马萨诸塞州牛顿设有办事处，是一家分子诊断公司，专注于通过表观遗传生物标志物检测提高癌症诊断和治疗决策的准确性。该公司专注于开发和商业化检测与泌尿系统癌症相关的 DNA 甲基化变化的测试，从而实现更精确的风险分层和患者管理。</p>
<p>MDxHealth 的主要产品组合包括 ConfirmMDx 和 SelectMDx。</p>
<h2>阅读更多</h2>
<ul>
<li>我们更看好的五只股票比 MDxHealth 更好</li>
<li>华尔街股票挑选者评选 2026 年第一只股票</li>
<li>“6.6 万亿美元的客户银行存款面临风险”</li>
<li>华盛顿为战争做准备</li>
<li>崩盘前一个月</li>
<li>现在就抛掉这五只股票！</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 MDxHealth 吗？</h2>
<p>在考虑 MDxHealth 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在就买入，以便在更广泛的市场注意到之前...而 MDxHealth 并不在名单上。</p>
<p>虽然 MDxHealth 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

MDXH

<p>MDxHealth SA (NASDAQ:MDXH) 在 12 月份的空头头寸大幅下降，至 12 月 15 日减少了 42.6%，降至 15,027 股。当前的空头头寸比率为 0.1 天。该股票在周五下跌了 1.7%，报 3.41 美元。分析师对该股票给予了 “适度买入” 的共识评级，目标价格为 7.75 美元。MDxHealth 专注于癌症的分子诊断，主要产品包括 ConfirmMDx 和 SelectMDx</p>

<p>MDxHealth SA (NASDAQ:MDXH - Get Free Report) was the target of a large decrease in short interest in December. As of December 15th, there was short interest totaling 15,027 shares, a decrease of 42.6% from the November 30th total of 26,198 shares. Based on an average daily trading volume, of 122,196 shares, the days-to-cover ratio is presently 0.1 days. Currently, 0.0% of the company's stock are sold short. Currently, 0.0% of the company's stock are sold short. Based on an average daily trading volume, of 122,196 shares, the days-to-cover ratio is presently 0.1 days.</p>
<div class="lb-trans"><p>MDxHealth SA (NASDAQ:MDXH - 获取免费报告) 在 12 月份的空头头寸大幅减少。截至 12 月 15 日，空头头寸总计 15,027 股，比 11 月 30 日的 26,198 股减少了 42.6%。根据 122,196 股的平均日交易量，当前的覆盖天数比率为 0.1 天。目前，公司股票的空头比例为 0.0%。</p>
</div><h2>MDxHealth Trading Down 1.7%</h2>
<div class="lb-trans"><h2>MDxHealth 股价下跌 1.7%</h2>
</div><p>NASDAQ:MDXH traded down $0.06 on Friday, reaching $3.41. The company's stock had a trading volume of 42,254 shares, compared to its average volume of 110,342. The stock has a 50 day moving average price of $3.84 and a 200 day moving average price of $3.37. MDxHealth has a 12-month low of $1.35 and a 12-month high of $5.33. The company has a quick ratio of 1.02, a current ratio of 1.14 and a debt-to-equity ratio of 13.81. The firm has a market cap of $161.26 million, a price-to-earnings ratio of -5.33 and a beta of 1.59.</p>
<div class="lb-trans"><p>NASDAQ:MDXH 周五下跌 0.06 美元，报 3.41 美元。该公司的股票交易量为 42,254 股，而其平均交易量为 110,342 股。该股票的 50 日移动平均价格为 3.84 美元，200 日移动平均价格为 3.37 美元。MDxHealth 的 12 个月低点为 1.35 美元，12 个月高点为 5.33 美元。该公司的速动比率为 1.02，流动比率为 1.14，债务股本比率为 13.81。该公司的市值为 1.6126 亿美元，市盈率为-5.33，贝塔值为 1.59。</p>
</div><p>MDxHealth (NASDAQ:MDXH - Get Free Report) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.04). MDxHealth had a negative net margin of 30.50% and a negative return on equity of 1,078.01%. The company had revenue of $27.43 million during the quarter, compared to analysts' expectations of $24.11 million. On average, equities analysts anticipate that MDxHealth will post -1.15 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>MDxHealth (NASDAQ:MDXH - 获取免费报告) 最近于 11 月 12 日发布了季度财报。该公司报告每股收益（EPS）为-0.16 美元，低于分析师一致预期的-0.12 美元，差距为 0.04 美元。MDxHealth 的净利润率为-30.50%，股本回报率为-1,078.01%。该公司在本季度的收入为 2743 万美元，而分析师预期为 2411 万美元。平均而言，股票分析师预计 MDxHealth 在当前财政年度的每股收益为-1.15 美元。</p>
</div><h2>Institutional Trading of MDxHealth</h2>
<div class="lb-trans"><h2>MDxHealth 的机构交易</h2>
</div><p>Large investors have recently modified their holdings of the stock. GSA Capital Partners LLP purchased a new stake in MDxHealth during the 3rd quarter worth about $48,000. Lido Advisors LLC acquired a new position in MDxHealth during the third quarter worth approximately $48,000. Citadel Advisors LLC raised its position in MDxHealth by 30.6% in the 3rd quarter. Citadel Advisors LLC now owns 48,938 shares of the company's stock valued at $228,000 after purchasing an additional 11,456 shares during the last quarter. Jefferies Financial Group Inc. acquired a new stake in shares of MDxHealth during the third quarter worth about $53,000. Finally, Bank of America Corp DE increased its position in MDxHealth by 5,164.0% in the 3rd quarter. Bank of America Corp DE now owns 15,055 shares of the company's stock valued at $70,000 after acquiring an additional 14,769 shares during the period.</p>
<div class="lb-trans"><p>大型投资者最近调整了对该股票的持有。GSA Capital Partners LLP 在第三季度购买了 MDxHealth 的新股份，价值约 48,000 美元。Lido Advisors LLC 在第三季度获得了 MDxHealth 的新头寸，价值约 48,000 美元。Citadel Advisors LLC 在第三季度将其在 MDxHealth 的持股增加了 30.6%。Citadel Advisors LLC 目前拥有 48,938 股该公司的股票，价值 228,000 美元，此前在上个季度购买了 11,456 股。Jefferies Financial Group Inc.在第三季度获得了 MDxHealth 的新股份，价值约 53,000 美元。最后，Bank of America Corp DE 在第三季度将其在 MDxHealth 的持股增加了 5,164.0%。Bank of America Corp DE 目前拥有 15,055 股该公司的股票，价值 70,000 美元，此前在该期间内购买了 14,769 股。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>A number of equities analysts have recently issued reports on MDXH shares. Weiss Ratings reiterated a &#34;sell (e+)&#34; rating on shares of MDxHealth in a research note on Wednesday, October 8th. Wall Street Zen upgraded shares of MDxHealth to a &#34;hold&#34; rating in a report on Saturday, August 30th. Lake Street Capital raised their target price on MDxHealth from $7.00 to $9.00 and gave the stock a &#34;buy&#34; rating in a research note on Thursday, November 13th. BTIG Research reaffirmed a &#34;buy&#34; rating and issued a $7.00 price objective on shares of MDxHealth in a report on Tuesday, December 23rd. Finally, TD Cowen raised their target price on MDxHealth from $5.00 to $7.00 and gave the stock a &#34;buy&#34; rating in a report on Thursday, November 13th. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, MDxHealth presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $7.75.</p>
<div class="lb-trans"><p>一些股票分析师最近对 MDXH 股票发布了报告。Weiss Ratings 在 10 月 8 日的研究报告中重申了对 MDxHealth 股票的 “卖出（e+）” 评级。Wall Street Zen 在 8 月 30 日的报告中将 MDxHealth 股票的评级上调至 “持有”。Lake Street Capital 在 11 月 13 日的研究报告中将 MDxHealth 的目标价格从 7.00 美元上调至 9.00 美元，并给予该股票 “买入” 评级。BTIG Research 在 12 月 23 日的报告中重申了 “买入” 评级，并对 MDxHealth 股票设定了 7.00 美元的目标价。最后，TD Cowen 在 11 月 13 日的报告中将 MDxHealth 的目标价格从 5.00 美元上调至 7.00 美元，并给予该股票 “买入” 评级。四位分析师对该股票给予了买入评级，一位分析师对该公司的股票给予了卖出评级。根据 MarketBeat.com 的数据，MDxHealth 目前的共识评级为 “适度买入”，共识目标价格为 7.75 美元。</p>
</div><p><strong>View Our Latest Report on MDxHealth</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 MDxHealth 的最新报告</strong></p>
</div><h2>About MDxHealth</h2>
<div class="lb-trans"><h2>关于 MDxHealth</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.</p>
<div class="lb-trans"><p>MDxHealth 总部位于比利时梅赫伦，在美国马萨诸塞州牛顿设有办事处，是一家分子诊断公司，专注于通过表观遗传生物标志物检测提高癌症诊断和治疗决策的准确性。该公司专注于开发和商业化检测与泌尿系统癌症相关的 DNA 甲基化变化的测试，从而实现更精确的风险分层和患者管理。</p>
</div><p>MDxHealth's lead product portfolio includes ConfirmMDx and SelectMDx.</p>
<div class="lb-trans"><p>MDxHealth 的主要产品组合包括 ConfirmMDx 和 SelectMDx。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>阅读更多</h2>
</div><ul>
<li>Five stocks we like better than MDxHealth</li>
<li>Wall Street Stockpicker Names #1 Stock of 2026</li>
<li>“$6.6 Trillion Of Customer Bank Deposits At Risk”</li>
<li>Washington prepares for war</li>
<li>A month before the crash</li>
<li>Drop these 5 stocks now!</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 MDxHealth 更好</li>
<li>华尔街股票挑选者评选 2026 年第一只股票</li>
<li>“6.6 万亿美元的客户银行存款面临风险”</li>
<li>华盛顿为战争做准备</li>
<li>崩盘前一个月</li>
<li>现在就抛掉这五只股票！</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in MDxHealth Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 MDxHealth 吗？</h2>
</div><p>Before you consider MDxHealth, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 MDxHealth 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MDxHealth wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在就买入，以便在更广泛的市场注意到之前...而 MDxHealth 并不在名单上。</p>
</div><p>While MDxHealth currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 MDxHealth 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

MDxHealth SA（NASDAQ 代码：MDXH）空头头寸更新